David Buswell CEO Immune Response Biopharma responds to questions

Below is Mr. Buswell's reply to my letter.



From David Buswell, CEO Immune Response BioPharma

GOTO HELL

---

From: Joel Reese
Sent: Tuesday, June 18, 2013 1:57 PM
To: David Buswell
Subject: Investment with Immune Response BioPharma

 

Dear Mr. Buswell:   I am very impressed with the description of Immune Response BioPharma on your company's website. It seems you have a number of drugs in development any one of which would be of great benefit to those who suffer from these terrible diseases. If just one of these drugs should gain approval Immune Response BioPharma could become profitable in a very short time.   I am also aware that your company is attempting to use research from the Immune Response/Orchestra Corporation in an attempt to raise funding for Immune Response BioPharma. As a long time investor in IMNR/OCHT still holding 64,483 shares I wish to advise you that the research was not abandoned by its investors and I feel that illegal manipulation of the IMNR/OCHT stock and ownership was used to basically steal its research and cheat its creditors in an attempt to create what you now call Immune Response Biophama. Your company boasts a great deal of what the legality of what it is doing, but I say to you that it is immoral, unfair, and unwise to simply abandon the stock holders who financed the research you now claim to own without offering to make their stock holdings now part of the new company or offering them fair payment for their stock. I don't know what if anything the owners of IMNR/OCHT stock can do at this point legally to protect their rights, but I can assure you that I will make every effort to see that I am not cheated and to let other potential investors of yours know of your company's history and connection to IMNR/OCHT to prevent what happened to us from happening to them. There is such a thing as right and wrong and what you are attempting to do is clearly wrong. I am writing to inquire if Kevin Kimberlin who purchased property rights to research at IMNR/OCHT through Spencer Trask is involved in the Immune Response BioPharma Corporation and what his role is? I am sure that  Spencer Trask, David Buswell, and Immune Response BioPharma wish to be honorable in how they handle this and treat the investors of IMNR fairly. Thank you for your consideration and assistance.

Immune Response Incorporated

The message board for Orchestra on yahoo is still active under OCHTQ. There doesn't seem to be much progress being made for Immune Response Biopharma other than changes on their website.

Immune Response, Orchestra, and Immune Response Biophrama

Immune Response BioPharma has issued a press release (Jan. 7, 2013) citing its 2012 highlights and its goals for 2013. The Immune Response Corp began originally under Dr. Jonas Salk in 1986-87 seeking a vaccine to treat HIV. By April, 1990 the biotechnology company had filed to hold a 2.2-million share initial public stock offering that was expected to raise as much as 19.8 million. By September, 1991, Immune Response was the hottest biotechnology issue on the market with shares climbing from a January 1991 price of $2.875 to $32.625 in over-the-counter trading based on its HIV therapeutic vaccine which was said to be in the advanced stages of clinical trails. In 1998 Immune Response signed a deal with Agouron Pharmaceuticals Inc. a unit of Pfizer as a developing and marketing pact for its AIDS drug.

The problem was that the test results were either disappointing or were challenged as being poorly designed and therefore unreliable. By July 7, 2001 shares of Immune Response plunged 44% after Pfizer discontinued development of the drug and ended its association with Immune. By September 2002, Dennis Carlo, the companies CEO had resigned and the company was forced to cut half its staff. The company's auditors publicly questioned the ability of Immune Response to continue to operate. Despite years and years of testing and research the company was still unable to prove that Remune, the vaccine it developed to treat HIV, was effective. In March of 2007 the company had moved on and was injecting its first patient in a large multi-center Phase II study of NeuroVax(TM) its multiple sclerosis vaccine. NeuroVax(TM) was based on the company's patented T-cell receptor peptide vaccine technology.

By October 2008 the company had filed for bankruptcy. At the time the company listed $32.61 million in liabilities and $1.64 million in assets. Now, in 2013, nearly 27 years after Dr. Salk first founded the company Immune Response continues trying to prove the value of Remune and NeuroVax as well as other vaccines developed by the company years ago. It claims to to have plans to partner with large pharma partners and to be on track for record growth and profits in the future. Financing for the company for now remains a mystery as does the results of any recent studies.

Immune Response and 2013

I just wanted to thank the many people around the world who have visited and viewed my blog over the past year. Looking toward 2013 I will continue to work on behalf of my fellow investors in Immune Response/Orchestra Therapeutics and seek to protect our rights concerning Immune Response Biopharma. The research they now seek to exploit was financed and supported for nearly twenty years by investors including myself. Though they claim to be a new and separate company all their research was in fact conducted and financed more than ten years ago. Hopefully investors like myself will be able to convince Immune Response Biopharma to deal fairly with the original investors.

Immune Response BioPharma and Immune Response Corp. research.

The present company of Immune Response Biopharma which is really just the old Immune Response Incorporated or Orchestra Therapeutics has a really impressive website. It shows that the current incarnation of Immune Response/Orchestra is called the Immune Response BioPharma and seems to be made of people and research the company had nearly 15 years ago. Dr. Richard Bartholomew and Dr. Arthur Vandenbard, all go back into the 90s with Immune Response Inc.  The research they are now touting is actually research conducted nearly 15 years ago. Their recent press release on REMUNE, Oct. 31, 1912, sites Study 806 which was terminated in 1999. Its hard to believe that people would invest in clinical test results that old which were conducted by a company that then went Chapter 11 defrauding both their creditors and investors out of all their money. The website seems to be designed to lure unsuspecting investors and supporters. I along with most others who invested in this research lost all my money and ended up bankrupt with nothing. I just hope the same thing doesn't happen again to investors.

Immune Response

Over 2,500 people have viewed this blog since it was first created. Seems a lot of people are interested in the connection between Immune Response/Orchestra and Immune Response BioPharma.

David Buswell and Dennis Carlo

The annoucement by David Buswell that Immune Response BioPharma was being dumped by GSK sounds just like the sort of statements that Dennis Carlo, former president and CEO of Immune Response used to put out. I wonder if they are one and the same person. The two companies seem to be one and the same. Hard to imagine there could be two CEOs who would issue statements like this.

May 24, 2012.
"Immune Response BioPharma, Inc. has the first MS Vaccine a first in class and best in class multiple sclerosis drug which restores deficient FOXP3+ T-Regs. GSK has no approved MS drug and probably will never have one they are busy wasting their shareholders money on HGSI and a Lupus drug with poor sales, we don't need them or to give away our blockbuster drug for MS to them which we believe will become treatment of choice" IRBP CEO Mr. Buswell

"IRBP values NeuroVax north of a billion dollar of annual sales once approved. We will find a solid partner or raise capital on our own, we don't need GSK which has zer0 experience in multiple sclerosis or auto-immune diseases. GSK is a joke and seems very ignorant on how multiple sclerosis drugs work and how to develop one, we gave them a chance to develop NeuroVax but their management appears to be very poor. We have decided to terminate any collaboration or development with GSK. GSK is a loser in the MS market and will continue to be a loser" IRBP CEO Mr. Buswell